Market revenue in 2024 | USD 6,522.2 million |
Market revenue in 2030 | USD 8,026.9 million |
Growth rate | 3.5% (CAGR from 2025 to 2030) |
Largest segment | Reagents product |
Fastest growing segment | Others Product |
Historical data covered | 2018 - 2023 |
Base year for estimation | 2024 |
Forecast period covered | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Instruments Product, Reagents Product, Others Product |
Key market players worldwide | Abbott Laboratories, Danaher Corp, BioMerieux SA, Roche Holding AG ADR, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Becton Dickinson & Co, Hologic Inc, Illumina Inc, Grifols SA Ordinary Shares - Class A, Qiagen NV, Siemens Healthineers AG ADR, Sysmex Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to infectious disease molecular diagnostics market will help companies and investors design strategic landscapes.
Reagents product was the largest segment with a revenue share of 67.67% in 2024. Horizon Databook has segmented the North America infectious disease molecular diagnostics market based on instruments product, reagents product, others product covering the revenue growth of each sub-segment from 2018 to 2030.
North American market held the highest market share owing to increasing adoption of molecular diagnostics, due to their high accuracy, sensitivity, and specificity. Increasing need for molecular testing to detect infectious diseases, for early detection of infections in patients with underlying medical conditions, such as diabetes, and rising number of drugresistant infections are major market drivers.
There has been an increase in the number of strategic partnerships between major pharmaceuticals and molecular diagnostics manufacturing companies, to develop infectious disease molecular diagnostics, which can be attributed to the COVID-19 pandemic.
The recent novel coronavirus pandemic is expected to positively impact market growth. By September 2020, the U.S. had used over 150 million molecular diagnostic tests for detection of COVID-19 virus infection. However, shortage of the supply of materials, such as reagents, required to perform diagnostic tests is expected to impede market growth.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America infectious disease molecular diagnostics market , including forecasts for subscribers. This continent databook contains high-level insights into North America infectious disease molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account